AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05480527 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous pulsed radiofrequency current
Description: Active treating group: 80 volts, 2Hz, 20 ms pulsed radiofrequency current will be applied to the tibial nerve trace in the ankle with electrodes. Sham group: Elelctrodes will be attached but radiofrequency current will not be applied.
Study NCT05480527 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous pulsed radiofrequency current
Description: Active treating group: 80 volts, 2Hz, 20 ms pulsed radiofrequency current will be applied to the tibial nerve trace in the ankle with electrodes. Sham group: Elelctrodes will be attached but radiofrequency current will not be applied.
Study NCT02442752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole capsules
Study NCT06389604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat acclimation
Description: Daily repeated heat exposure to assess the effects of combined passive and active heat acclimation
Study NCT05238727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.8 ml mepivacaine hydrochloride
Description: 1.8 ml mepivacaine IANB
Study NCT05238727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.6 ml mepivacaine hydrochloride
Description: 3.6 ml mepivacaine IANB
Study NCT05238727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.8 ml mepivacaine hydrochloride IANB plus 1.8 ml articaine hydrochloride BI
Description: 1.8 ml mepivacaine IANB plus 1.8 ml articaine BI
Study NCT06305637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole Shampoo, 2%
Description: The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
Study NCT06305637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole Shampoo, 2% (Reference Standard)
Description: The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
Study NCT06305637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
Study NCT05115851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal tDCS cerebellar stimulation group
Description: three-session ctDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
Study NCT05115851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal tDCS cerebral (M1) stimulation group
Description: three-session a-tDCS (2 mA, 20 min), the anode will be positioned over the lesioned M1 (C3, International 10-20 system) and the cathode would be located over the supraorbital area. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
Study NCT05115851 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Group
Description: three-session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
Study NCT05272111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBM fasciatherapy+ conventional physical therapy
Description: DBM fasciatherapy (3 sessions per day). It soft, deep and non-manipulative form of treatment that involves the application of gentle pressure while stretching the body's connective tissue. A specialized form of touch, somatic sense, and specific body movement protocols are the three steps involved in the fasciatherapy. + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation). A total of 45 min session three times a week on alternate days for three weeks
Study NCT05272111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fascial manipulation+ conventional physical therapy
Description: Fascial manipulation (3 sessions per day). This technique involves the identification of specific, localized areas of the fascia with limited movements. Once it is identified, then a specific point on the fascia is targeted and through the appropriate manipulation of this precise part of the fascia, movement can be restored. + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation). A total of 45 min session three times a week on alternate days for three weeks
Study NCT06104020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative fluid management stratigies.
Description: Regimens of different intraoperative fluid management The restrictive fluid group (RG) aims to achieve a net zero fluid balance and involves a 2 mL/kg bolus at anesthesia induction, followed by an intraoperative crystalloid infusion at a rate of 4 mL/kg/hr.~The other group of patients, the liberal group (LG), will receive a 10 ml/kg bolus at anesthesia induction,followed by an intraoperative crystalloid infusion at a rate of 8 ml/kg/hr.
Study NCT05014594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin (10Mg Tab) along with standard medical therapy
Description: Oral Dapaglifozin (10 mg/day) along with standard medical therapy will be given to Group A while a placebo of dapaglifozin along with standard medical therapy will be used in Group B
Study NCT05014594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of dapaglifozin along with standard medical therapy
Description: Standard medical therapy will include dietary restriction of sodium, treatment with diuretics, repeated LVP as needed and other supportive care. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
Study NCT06388343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of Children's Listening and Processing Skills
Description: The Evaluation of Children's Listening \& Processing Skills (ECLiPS; (Barry \& Moore, 2021; Barry et al., 2015; Petley et al., 2021) is a caregiver-report outcome measure to profile auditory and cognitive real-world abilities important for successful listening and (auditory) processing.
Study NCT06388343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of Children's Listening and Processing Skills
Description: The Evaluation of Children's Listening \& Processing Skills (ECLiPS; (Barry \& Moore, 2021; Barry et al., 2015; Petley et al., 2021) is a caregiver-report outcome measure to profile auditory and cognitive real-world abilities important for successful listening and (auditory) processing.
Study NCT06388343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary behavioral assessment
Description: By collecting behavioral measures, the investigators wish to understand the functional implications of the presented problems. Children will complete various well-chosen tasks using a tablet, in the presence of a trained clinician. Tablets are used as they are ubiquitous, cost-effective, and have excellent quality audio output. The investigators will apply the concept of differential testing (Dillon \& Cameron, 2021; Lagacé et al., 2010) to narrow down the range of deficits that lead to deficient scores. The investigators distinguish four (partly overlapping) categories of behavioral measures: 1) auditory processing, 2) (nonsense) speech sound processing in quiet and in noise, excluding semantics, 3) meaningful speech in quiet and in noise, language processing, and 4) neurocognitive (including attention, memory, processing speed) processing.
Study NCT06388343 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary behavioral assessment
Description: By collecting behavioral measures, the investigators wish to understand the functional implications of the presented problems. Children will complete various well-chosen tasks using a tablet, in the presence of a trained clinician. Tablets are used as they are ubiquitous, cost-effective, and have excellent quality audio output. The investigators will apply the concept of differential testing (Dillon \& Cameron, 2021; Lagacé et al., 2010) to narrow down the range of deficits that lead to deficient scores. The investigators distinguish four (partly overlapping) categories of behavioral measures: 1) auditory processing, 2) (nonsense) speech sound processing in quiet and in noise, excluding semantics, 3) meaningful speech in quiet and in noise, language processing, and 4) neurocognitive (including attention, memory, processing speed) processing.
Study NCT06308939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.4mg/m\^2 day1、8，repeated every 3 week.
Study NCT06308939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 500mg once every three weeks.
Study NCT06183801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics 1
Description: Subjects take probiotics capsule(Lactobacillus fermentum,TSF331) three times a day before meal.
Study NCT06183801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics 2
Description: Subjects take probiotics capsule(Lactobacillus reuteri,TSR332) three times a day before meal.
Study NCT06183801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics 3
Description: Subjects take probiotics capsule(Lactobacillus plantarum,TSP05) three times a day before meal.
Study NCT06183801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics 4
Description: Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05) three times a day before meal.
Study NCT06183801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics 5
Description: Subjects take probiotics capsule(Lactobacillus fermentum,TSF331+Lactobacillus reuteri,TSR332+Lactobacillus plantarum,TSP05+Postbiotics PE0401) three times a day before meal.
Study NCT06183801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Subjects take capsule three times a day before meal.
Study NCT06183801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics 6
Description: After 1 month wash out, subjects take probiotics capsule(Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.
Study NCT06183801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics 7
Description: After 1 month wash out, subjects take probiotics capsule(Lactobacillus rhamnosus, bv-77+Bifidobacterium animalis subsp. lactis,CP-9) three times a day before meal.
Study NCT06183801 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: After 1 month wash out, subjects take capsule three times a day before meal.
Study NCT05605119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR105
Description: Once daily
Study NCT04634604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.
Study NCT04634604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by OSHA and facility standards, will be followed.
Study NCT06529588 — intervention group
Intervention type: RADIATION
Intervention: Radiation
Description: HNCs patients who received radiotherapy was exposure (5700-7000 Gys) for fractions number (32-35) after 6 months
Study NCT06226896 — intervention group
Intervention type: DRUG
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10mg daily plus RAS inhibitor
Study NCT05225818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAN - Home
Description: home-based intervention program for dementia evaluation, education, and care planning
Study NCT06486740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mesofiller aox
Description: The investigated product M-AOX-2021 was applied by intradermal or subcutaneous injection by the investigator during Session 1 for all subjects and Session 2 for the subjects, for whom a touch-up was considered beneficial. The both sessions was conducted within 14 days interval.
Study NCT05094323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine
Description: Patients will receive ultrasound-guided deep serratus anterior plane block with isobaric bupivacaine.
Study NCT05094323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local wound infiltration with isobaric bupivacaine
Description: Patients will receive local wound infiltration with isobaric bupivacaine.
Study NCT05094323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound-guided thoracic paravertebral block with isobaric bupivacaine
Description: Patients will receive ultrasound-guided thoracic paravertebral block with isobaric bupivacaine.
Study NCT05639946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brivaracetam
Description: Drug dosage will be individually titrated for each participant with a goal of 100mg BID according to the following dose escalation protocol that we use clinically: 50mg BID for 2 weeks, followed by 50mg TID for 2 weeks, followed by 100mg BID for 48 days as tolerated. Participants will be allowed to reduce the dose of brivaracetam if they experience unacceptable side effects defined as increased somnolence according to routine clinical practice with other drugs in this class used for pain.
Study NCT05639946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo drug
Study NCT06554288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl
Description: 6-week dose escalation up to 0.25mg/kg TID, followed by a 9-week maintenance period at this dose
Study NCT06636552 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Daratumumab (Subcutaneously)
Description: D-PAD (21-Day Cycles 1, 3 and 5):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycles 1 and 3) 1,800 mg (Q3W) SC on day 1 (for Cycle 5)~D-CVD (21-Day Cycles 2, 4, 6, 7 and 8):~1,800 mg (QW) SC on days 1, 8, and 15 (for Cycle 2) 1,800 mg (Q3W) SC on day 1 (for Cycles 4, 6, 7 and 8)~Daratumumab monotherapy (28-Day Cycles 9 to 32):~1,800 mg (Q4W) SC on day 1
Study NCT05802810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]JT001
Description: Subjects will receive approximately 300 mg/100 µCi of \[14C\]JT001 orally.
Study NCT05787418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH-120 Nasal Spray
Description: HH-120 nasal spray 8 times per day for 7 consecutive days
Study NCT05787418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 8 times per day for 7 consecutive days
Study NCT06582615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo dried blood spot collection
Study NCT06582615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo dried blood spot collection
Study NCT06582615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Ancillary studies
Study NCT06582615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Assessment
Description: Ancillary studies
Study NCT06582615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive MIND counseling sessions
Study NCT06582615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Follow a personalized diet
Study NCT06582615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: Receive general health recommendations counseling sessions
Study NCT06582615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear a Fitbit
Study NCT06582615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear a Fitbit
Study NCT06582615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06582615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06401148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehab intervention group
Description: Participants will complete an 8-week cardiac rehabilitation programme supported by the onsite CR service.
Study NCT06543979 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lubiprostone , single arm
Description: laxative
Study NCT06543979 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: biofeed back sessions
Description: Biofeedback for participants with dyssynergic defecation and participants with reduced rectal sensations
Study NCT06543979 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: botox injection
Description: Botulinum toxin injection for participants suffering from elevated anal canal pressure
Study NCT06088654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH6501
Description: phase 1 (dose finding) and phase 2 (dose expansion)
Study NCT06230757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 25mg
Description: 25mg psilocybin capsule
Study NCT06230757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (active placebo)
Description: 1mg psilocybin capsule
Study NCT05307055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN DBS - Theta Burst
Description: 200 Hz intraburst stimulation for 0.1 second repeated at intervals of 5hz with an existing device
Study NCT05307055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN DBS - Gamma
Description: Standard of care gamma stimulation with an existing device
Study NCT05493280 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MOXI
Description: Patients will receive treatment using f1927 devices and will be treated over the affected areas, once each month for a total of three months.
Study NCT06042894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
Study NCT06042894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: SI-B003 was administered by intravenous infusion on D1 in a 3-week cycle.
Study NCT06398145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol and lactalbumin (high dose)
Description: From 0 to 3 months: 1200mg D-chiro-inositol and 120mg lactalbumin per day
Study NCT06398145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol and lactalbumin (low dose)
Description: From 3 to 6 months: 600mg D-chiro-inositol and 60mg lactalbumin per day
Study NCT04262375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
Study NCT04262375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.
Study NCT06459921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX+Sintilimab
Description: Patients would be allocated to the SOX+Sintilimab group.